COLL Collegium Pharmaceutical Inc.

Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024

Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024

STOUGHTON, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report third quarter 2024 financial results after the market closes on Thursday, November 7, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.

Conference Call Information 

To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q3 2024 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: . The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Collegium Pharmaceutical, Inc.

Collegium is a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at .

Investor Contact:

Danielle Jesse                                                                                       

Director, Investor Relations

Media Contact:

Marissa Samuels

Vice President, Corporate Communications

 



EN
24/10/2024

Underlying

COLLCollegium Pharmaceutical Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Collegium Pharmaceutical Inc.

 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Report Third Quarter 2024 Financial Results on November 7...

Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024 STOUGHTON, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report third quarter 2024 financial results after the market closes on Thursday, November 7, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Information To access the conference call, please ...

October 24, 2024 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 46.09
SHAK Shake Shack In...
PLAY Dave & Buster's... ... (+65)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

SHAK SHAKE SHACK INC. CLASS A
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
OCUL OCULAR THERAPEUTIX
HNRG HALLADOR ENERGY CO.
EAT BRINKER INTERNATIONAL INC.
DECK DECKERS OUTDOOR CORPORATION
CSIQ CANADIAN SOLAR INC.
COLL COLLEGIUM PHARMACEUTICAL INC.
CALM CAL-MAINE FOODS INC.
CAKE CHEESECAKE FACTORY INCORPORATED
BBW BUILD-A-BEAR WORKSHOP
ASPN ASPEN AEROGELS
APOG APOGEE ENTERPRISES INC.
AMSC AMERICAN SUPERCONDUCTOR CORP.
ALB ALBEMARLE CORPORATION
AAOI APPLIED OPTOELECTRONICS INC.
COF CAPITAL ONE FINANCIAL CORPORATION
ZUMZ ZUMIEZ INC.
VFC V.F. CORPORATION
CRVS CORVUS PHARMACEUTICALS
DESP DESPEGAR.COM CORP.
FNKO FUNKO CLASS A
AMD ADVANCED MICRO DEVICES INC.
ACMR ACM RESEARCH
PPIH PERMA PIPE INTERNATIONAL HOLDINGS
GLOB GAZIT-GLOBE LTD.
PLMR PALOMAR HOLDINGS
CAPR CAPRICOR THERAPEUTICS
CRMD CORMEDIX INC.
BILL BILL.COM HOLDINGS
ADPT ADAPTIVE BIOTECHNOLOGIES
GII SPDR S&P GLOBAL INFRASTRUCTURE
TVTX TRAVERE THERAPEUTICS INC
VHI VALHI INC.
ALKT ALKAMI TECHNOLOGY INC
SOFI SOFI TECHNOLOGIES INC
EVGO EVGO INC
ENVX ENOVIX CORP
TSE TRINSEO PLC
ASTS AST SPACEMOBILE INC
PLL PIEDMONT LITHIUM INC
MLTX MOONLAKE IMMUNOTHERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
FTAI FORTRESS TRANSN & INFRAS INVS LLC
RDW REDWIRE CORP
COYA COYA THERAPEUTICS INC
SKWD SKYWARD SPECIALTY INS GROUP INC
MLYS MINERALYS THERAPEUTICS INC
ELVN IMARA INC
WGS GENEDX HOLDINGS CORP.
KGS KODIAK GAS SERVICES INC
BYRN BYRNA TECHNOLOGIES INC
NMRA NEUMORA THERAPEUTICS INC
ATGL ALPHA TECHNOLOGY GROUP LTD
NGNE NEUROGENE INC
DAVE DAVE INC
LENZ LENZ THERAPEUTICS INC
IBTA IBOTTA INC
FIP FTAI INFRASTRUCTURE INC
CLMT CALUMET INC
NUTX NUTEX HEALTH INC
DOGZ DOGNESS INTERNATIONAL CORP
TECX TD GLOBAL TECHNOLOGY LEADERS CAD HEDGED INDEX ETF
TBNK TD CANADIAN BANK DIVIDEND INDEX ETF
RDDT REDDIT INC
10/08/24 October 8, 2024 1 EN
Free Trial
COLL Collegium Pharm...

Collegium Pharmaceutical Inc: 1 director

A director at Collegium Pharmaceutical Inc sold 9,593 shares at 36.623USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...

COLL COLLEGIUM PHARMACEUTICAL INC.
09/18/24 September 18, 2024 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Completes Acquisition of Ironshore Therapeutics

Collegium Completes Acquisition of Ironshore Therapeutics – Adds Commercial Product Jornay PM®, Establishing Collegium’s Presence in Neurology (ADHD) – – Collegium Updates 2024 Financial Guidance to Reflect Expected Immediate Accretion from the Ironshore Acquisition – – 2024 Product Revenues, Net Expected in the Range of $620.0 Million to $635.0 Million – STOUGHTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it ...

September 4, 2024 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Participate in H.C. Wainwright 26th Annual Global Investm...

Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference STOUGHTON, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference being held in New York, NY from September 9-11, 2024. Details of the event are as follows:Fireside Chat Date and Time: Monday, September 9, 2024, at 12:30 p.m. ET T...

August 30, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch